REJENERA©, a multi-component bioflavonoid-based formula, alleviates osteoarthritis and provides chondroprotection by regulating the NLRP3-TXNIP-iNOS axis and inflammation: a comparative study with olive leaf nutraceuticals and ibuprofen
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Osteoarthritis (OA) primarly involves the degradation of joint cartilage and requires new treatments. REJENERA © , a newly developed nutraceutical formula against OA, contains primarily olive leaf bioflavonoids ( ZeyEX © , quercetin and luteolin), S -allylcysteine, palmitoylethanolamide, l -proline, hyaluronic acid and boron. This study focuses on the efficacy of REJENERA in treating knee OA and aims to compare it with ZeyEX, NPROC © (a product obtained by combining collagen-rich eggshell membrane with olive leaf extract), and IBUPROFEN in a rat OA model. OA was established by intra-articular injection of monosodium iodoacetate (MIA; 3 mg) into the right knee joints. Rats were either left untreated or treated orally for 12 weeks with REJENERA, ZeyEX, NPROC (300 mg/kg/day) or IBUPROFEN (3 mg/kg/day). MIA injection produced joint degeneration including increased fissure-index, osteophyte-score, and OARSI-score, joint swelling, synovial inflammation, proteoglycan loss, and decreased cartilage thickness. These histopathological abnormalities were partially but significantly alleviated by REJENERA and other treatments. Only ZeyEX significantly inhibited the OA-induced increase in IL-1β, IL-6, IL-10 and LPO in serum, and IL-6, TNF-α, and IFN-γ in synovial fluid. While increases in MMP-3 and MMP-9 were reduced with all treatments, MMP-13 was inhibited only by REJENERA. ZeyEX increased IL-2, NPROC increased IL-6, and IBUPROFEN inhibited IL-10. All treatments improved TIMP-1 levels; however, TXNIP was more significantly inhibited by ZeyEX, and NLRP3 by REJENERA. REJENERA’s anti-OA effects are accompanied by an increase in cartilage anabolic factors (Ki-67, type-II collagen, BMP-7) and inhibition of apoptosis. REJENERA offers a promising multi-targeted therapeutic approach to treating OA by blocking the iNOS-TXNIP-NLRP3 signaling axis, and reducing oxidative stress.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- REJENERA©, a multi-component bioflavonoid-based formula, alleviates osteoarthritis and provides chondroprotection by regulating the NLRP3-TXNIP-iNOS axis and inflammation: a comparative study with olive leaf nutraceuticals and ibuprofen
- Date Crossref
- 06/07/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ministry of Health pays non établi dans la noticeOrganisme public
-
Memorial Ankara Hospital pays non établi dans la noticeÉtablissement de santé
-
Gazi University pays non établi dans la noticeUniversité ou école supérieure
-
Ankara University pays non établi dans la noticeUniversité ou école supérieure
-
Gülhane Askerî Tıp Akademisi pays non établi dans la noticeÉtablissement de santé
-
Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Koç University pays non établi dans la noticeUniversité ou école supérieure
-
Inonu University Department of Medical Microbiology pays non établi dans la noticeUniversité ou école supérieure
-
Ankara Yıldırım Beyazıt University pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Medicine Department of Medical Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Ankara Dışkapı Training and Research Hospital Department of Orthopedics and Traumatology pays non établi dans la noticeÉtablissement de santé
-
Faculty of Pharmacy Department of Pharmacology pays non établi dans la noticeUniversité ou école supérieure
Ministry of Health, Memorial Ankara Hospital et Gazi University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.